Table 1.

Characteristics and survivals of the study’ patients ablated for naive HCC.

Variables	n = 1571
Age [years; median (IQR)]	62 (54–70)
<60 years	670 (42.6%)
60–70 years	538 (34.2%)
71–80 years	305 (19.4%)
>80 years	58 (3.7%)
Male gender	1197 (76.2%)
Eastern patients	886 (56.4%)
Year of ablation
2004–2008	166 (10.6%)
2009–2013	524 (33.3%)
2014–2018	881 (56.1%)
Etiology
Hepatitis B	774 (49.5%)
Hepatitis C	359 (22.9%)
Alcohol	235 (15.0%)
Other	253 (16.1%)
Total bilirubin [μmol/L; median (IQR)]	16.0 (11.0–23.8)
Serum albumin [g/L; median (IQR)]	40 (36–44)
ALBI grade
1	592 (37.7%)
2	866 (55.2%)
3	111 (7.1%)
MWA	217 (13.8%)
Largest tumour size [cm; median (IQR)]	2.5 (1.9–3.4)
Tumour number
Single	1176 (74.9%)
2 or 3 nodules	340 (21.6%)
4+ nodules	55 (3.5%)
BCLC very-early stage	317 (20.2%)
Milan IN	1358 (86.4%)
Disease-free survival [years; median (IQR)]	1.3 (0.5–3.6)
1 year (95% C.I.)	58.5% (55.9–60.9)
3 years (95% C.I.)	30.4% (27.9–32.9)
5 years (95% C.I.)	19.1% (16.4–21.4)
10 years (95% C.I.)	8.8% (6.1–12.3)
Overall survival [years; median (IQR)]	5.0 (2.2–9.6)
1 year (95% C.I.)	90.2% (88.5–91.6)
3 years (95% C.I.)	67.5% (64.8–70.2)
5 years (95% C.I.)	49.9% (46.6–53.2)
10 years (95% C.I.)	20.8% (16.0–26.1)